The two gene products of the CDKN2A gene, p16 and p19 ARF , have recently been linked to each of two major tumour suppressor pathways in human carcinogenesis, the RB1 pathway and the p53 pathway. p16 inhibits the phosphorylation of the retinoblastoma gene product by cyclin D-dependent kinases, whereas p19 ARF targets MDM2, a p53 inhibitory protein, for degradation. A deletion of CDKN2A would therefore disturb both pathways. To explore the p53 pathway genes as a functional unit in diffuse large B cell non-Hodgkin's lymphomas (DLCL), we wanted to see whether there exists mutually exclusiveness of aberrations of CDKN2A, MDM2 and p53, since this has not been analysed previously. We investigated 37 DLCL for aberrations of p15, p16, p19 ARF , MDM2, and p53 at the epigenetic, genetic and/or protein levels. Homozygous deletion of CDKN2A was detected in seven (19%) of 37 tumours, and another three cases were hypermethylated at the 5′ CpG island of p16. No point mutations were found in CDKN2B or CDKN2A. Immunohistochemical staining of formalin-fixed, paraffinembedded tissue for p16 confirmed these results, as all tumours with alterations of CDKN2A were p16 immunonegative. We found p53 mutations in eight (22%) cases and MDM2 overexpression in 16 (43%) tumours. Twenty-three (62%) tumours had alterations of one or more p53 pathway components (p53, p19 ARF and MDM2). Furthermore, 7/9 (78%) p16-immunonegative tumours showed co-aberration of p53 and/or MDM2. The lack of correlation between these aberrations suggests that DLCL acquire additional growth advantage by inactivating both of these critical regulatory pathways.
Introduction
The RB1 pathway and the p53 pathway are two major growth regulatory pathways involved in human tumorigenesis. Both pathways consist of a number of tumour suppressor genes and proto-oncogenes, which -if deregulated -promote the formation of cancer. The two most commonly altered genes in human cancer are CDKN2A (or p16 INK4a ) and p53 (or TP53) from the RB1 and the p53 pathway, respectively. The RB1 pathway exerts its tumour suppressor function primarily in the G1 phase of the cell cycle by inhibiting transcription of genes necessary for transition from G1 to S phase. 1 The p53 pathway regulates two end points: apoptosis and cell cycle arrest in G1, 2 depending on cell type and cell state. p53 acts as a transcription factor and interacts with other cellular proteins thereby exerting its tumour suppressor functions. 2 The protein product of the proto-oncogene MDM2 targets p53 for degradation through ubiquitin-mediated proteolysis. 3 Furthermore, MDM2 also binds p53 thereby transcriptionally silencing it, resulting in block of p53's apoptosis-and growth arrestinducing functions. 4 Recent research has linked the two path- ways together through the 9p21 locus. 5, 6 In this locus resides two cyclin-dependent kinase inhibitor genes, CDKN2A and CDKN2B. The CDKN2A gene has the rare ability to encode two different proteins, p16 and p19 ARF . This is due to the unusual organisation of the gene with two alternative first exons, exon 1␣ and exon 1␤, and common exons 2 and 3. 7, 8 Because they are translated in different reading frames p16 and p19
ARF are structurally unrelated. Despite this difference both can arrest the cell cycle in G1, albeit through different mechanisms. p16 inhibits CDK4/6 in the RB1 pathway, whereas p19
ARF interacts with the p53 pathway by binding to MDM2. 5, 6 The binding of p19 ARF to MDM2 promotes MDM2 degradation, thereby annulling MDM2's inhibition of p53. 5, 6 Hence, a mutation in CDKN2A potentially disrupts both the RB1 and p53 pathways. In the RB1 pathway mutations of CDKN2A and RB1 are inversely correlated in various human tumours 1 as are p53 mutations and MDM2 amplifications in soft tissue sarcomas 9 and gliomas 10 supporting that the genes are part of a functional unit. 1, 9, 10 The same could be expected for p53 and p19 ARF . 5 Diffuse large B cell lymphomas (DLCL), the non-Hodgkin's lymphoma subtype with the highest mortality and the largest increase in annual incidence increase, 11, 12 carry CDKN2A mutations (almost exclusively deletions) in 15-20% of cases, 13 mutated p53 15-20%, 14 and overexpression of MDM2 in up to 50%. 15, 16 To determine the status and correlations of the RB1 and p53 pathways in DLCL, we undertook a mutational analysis of p15, p16, p19 ARF and p53, as well as immunohistochemical detection of p16 and MDM2 in 34 patients with DLCL from a single institution. The present study is the first that reports the interrelations of aberrations of these cell cycle regualtory components in DLCL.
Materials and methods

Tissue material
Tumour specimens were obtained at the time of diagnosis (n = 34) and relapse (n = 3) from 34 patients at Odense University Hospital. Tumours were snap-frozen in liquid nitrogen and stored at −80°C in OCT compound (Miles, Elkhart, IN, USA). Adjacent non-frozen blocks were fixed in 10% buffered formalin and embedded in paraffin. The tumours were classified as DLCL according to the REAL classification. 17 The cases were subclassified as diffuse centroblastic (CB) or immunoblastic (IB) lymphomas according to the updated Kiel classification. 18 Two cases, 12.03 and 12.05, were IB, the remaining 35 tumours were CB. DNA was extracted from frozen tumour tissues using the QIAamp Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Prior to DNA extraction, the tumour tissues were examined to ensure that they consisted of viable tumour tissue with at least 50% tumour cells.
For determination of immunohistochemical reaction pat-terns of normal lymphoid tissues, two lymph nodes, one spleen and one tonsil without malignancy were randomly selected from the tissue files at Odense University Hospital. The tissues had been fixed in 10% buffered formalin and embedded in paraffin.
Immunohistochemistry for p16 and MDM2
The non-commercial mouse monoclonal anti-p16 antibody JC8 was evaluated along with the two commercial antibodies against p16, the monoclonal G175-405 and the polyclonal rabbit anti-human p16INK4 (PharMingen, San Diego, CA, USA). JC8 proved to be the superior antibody and was used in the present study. Formalin-fixed paraffin-embedded sections were stained using the assay described in detail elsewhere. 19 Two monoclonal antibodies against MDM2, Ab-1 clone IF2 (Oncogene Research, Cambridge, MA, USA) and NCL-MDM2 (Novocastra Laboratories, Newcastle upon Tyne, UK) were evaluated. IF2 was chosen for this study because of its greater reproducibility and reduced cytoplasmic staining (data not shown). Briefly, 4 m sections were deparaffinized, microwave oven antigen retrieved in T-EG buffer (10 mM Tris (Sigma, St Louis, MO, USA), 0.5 mM EGTA (Sigma), pH 9.0) and incubated overnight at 4°C with IF2 primary antibody in 1:100 dilution. TechMate 1000 (DAKO, Glostrup, Denmark) was used for automated staining using the LSAB+ kit (DAKO) with diaminobenzidine as chromogen and brief counterstaining in Mayer's hematoxylin.
Staining of normal germinal centres from tonsils and lymph nodes show weak staining of variable numbers of stromal cells such as follicular dendritic cells and weak staining of occasional lymphoid cells (present study and Nielsen, Stemmer-Rachamimov, Shaw, Koh, Louis, unpublished results). Based on this, a case was scored as p16 immunonegative if all malignant cells were unstained, while stromal cells or reactive non-malignant cells in the same section showed nuclear staining. If any malignant cells had nuclear staining the tumour was regarded as p16 positive. Tumours with strong p16 expression, ie Ͼ50% immunoreactive nuclei, were scored as strongly p16 immunopositive.
For evaluation of MDM2 immunoreactivity, only nuclear reaction was considered. An image analysis system consisting of an Olympus BX60 light microscope, a Sony CCD camera, and the image analysis software package ImagePro Plus (Media Cybernetics, Silver Spring, MD, USA) was used. A total of 22 high power fields (×400) of normal lymphoid tissue representing germinal centres, mantle zones and interfollicular areas were counted. On average 1.2% (0-4.4%) of the cells were MDM2 immunopositive. The germinal centres had the highest average percentage, 2.7% (0.2-4.4%), while the average percentage of MDM2-positive non-germinal centre fields was 0.3% (0-0.7%). Based on these controls, we defined MDM2 overexpression (MDM2+) as nuclear MDM2 immunopositivity of у10% of tumour cells.
Genetic analysis of CDKN2A and CDKN2B
Two previously decribed comparative multiplex PCR assays were used with minor modifications to detect homozygous deletions (HDs) of CDKN2A. 20, 21 The PCR programming was changed to a touch-down procedure with gradually decreasing annealing temperature from 62°C to 55°C. The products were visualised by ethidium bromide staining after electrophoresis on 3% agarose gels. All samples were run with both assays for confirmation.
Single-strand confirmation polymorphism (SSCP) analysis of CDKN2A exons 1, 2 and 3, and CDKN2B exon 2 was performed as published previously 22 except for modifications of the PCR amplification protocols: all five fragments (CDKN2A exon 1, 5′-half of exon 2, 3′-half of exon 2, exon 3, CDKN2B exon 2) were amplified using the touch-down protocol described.
SSCP of the alternative spliced exon 1␤ of CDKN2A was performed using previously published primers amplifying the exon 1␤ including intron-exon borders. 23 Amplification was done with 200 M dNTPs, 1.5 mM MgCl 2 , 1.0 M CDKN2A exon 1␤ primers, 0.5 U Taq polymerase, 5-50 ng genomic DNA, and 5% dimethylsulfoxide in 10-l reaction volumes. A touch-down PCR protocol was used with a first annealing temperature of 67°C and a last annealing temperature of 60°C. To increase the sensitivity of the SSCP assay the resulting 412-bp fragment was digested with FokI to generate fragments of 185 and 227 bp, respectively.
The PCR products were separated on 6% non-denaturing polyacrylamide gels with 10% glycerol overnight at 4-8 W. Cases with mobility shifts were reamplified and the fragments were gel purified from 2% agarose gels using the Compass Kit (American Bioanalytical, Natick, MA, USA). Purified fragments were sequenced with the T7 Sequenase kit (Amersham, Cleveland, OH, USA) using the SSCP primers.
For identification of hypermethylation of CpG islands of the promoter region of p16 we used a modification of the MSP assay 24 described previously. 19 PCR-RFLP analysis of CDKN2A exon 3 for identification of a common C to G polymorphism in the 3′ UTR was performed as described. 22 
Mutation analysis of p53
Denaturing gradient gel electrophoresis (DGGE)-based screening for mutations in the entire p53 coding sequence, ie exons 2-11, and splice junctions followed by cycle sequencing of fragments with deviant DGGE patterns was done as described 25 with the following exceptions: during PCR cresol red and sucrose were omitted, and DGGE was performed on gels containing a 30-80% gradient of urea and formamide. The gels were run at 150 V for 5 h.
Statistical analysis
Fisher's exact test was used to test for correlations of CDKN2A and p53/MDM2.
Results
CDKN2A and CDKN2B mutations
HD of CDKN2A was detected in seven (19%) of 37 DLCL biopsies from 34 patients (Table 1; Figure 1(a) ). In one of three patients with sequential biopsies available HD was present at relapse (11.08R) but not at the time of diagnosis (11.08). SSCP analysis of CDKN2A exons 1␣, 1␤, 2 and 3 as well as CDKN2B exon 2 revealed no tumour-specific migration shifts (Table 1) . DNA sequencing showed that a shift in the 3′-half exon 2 amplicon of case 11.09 was a common GCG to ACG polymorphism, changing alanine to threonine. Seven identical shifts were identified in the exon 3 fragments, one homozygous and six heterozygous, suggesting a frequent polymorphism. PCR-RFLP analysis of two of these cases confirmed the presence of the C/G polymorphism in base 494 of the 3′ UTR (data not shown).
p16 and MDM2 immunohistochemistry
All seven tumours with HD of CDKN2A were p16 immunonegative (Table 1 , Figure 2 (a) and (b) ). Of the remaining 28 tumours evaluated for p16, two were p16 negative and four were weakly p16 positive. In six cases, the p16 expression was strong. MDM2 was overexpressed in 16 of 37 (43%) lymphomas (Table 1 ; Figure 2 (c) and (d) ).
Hypermethylation of the CDKN2A promoter region
Seven DLCL cases that lacked CDKN2A HD, two p16 immunonegative, four weak p16 positive, and one not investigated immunohistochemically, were subjected to the MSP assay (Figure 1(b) ). Both p16-negative tumours as well as the tumour not investigated immunohistochemically amplified with the methylation-specific primers (Table 1) , as did the two colon carcinoma-positive control cell lines with known promoter region methylation, HT-29 and CaCo2. Conversely, none of the p16 weak-positive cases nor DNA from normal lymphoid tissue amplified with these primers, but showed amplification with the unmethylated base-specific primers. 
p53 mutations
Seven mutations were found in 37 tumours (Table 1 ). All seven mutations were base substituting missense mutations affecting the conserved hot-spot region of exons 5-8 ( Table 2) . In patient 11.21 the primary tumour and the recurrent tumour showed an identical p53 mutation.
Interrelations of alterations of p16, p19
ARF , p53 and MDM2
A summary of the alterations in the 37 DLCL is shown in Table 3 . One or more genes were altered in 23 (62%) of 37 lymphomas, and in nine (24%) tumours two or three genes were aberrant. Twenty-three (62%) tumours had alterations of one or more p53 pathway components (p53, p19 ARF and MDM2), with two (5%) patients (11.33 and 11.42) having alterations of all three components. MDM2 overexpression and p53 mutation were independent events (P = 1.00) with three tumours having both aberrations, five with p53 mutation only and 13 with MDM2 overexpression only. CDKN2A-deleted cases showed a trend towards correlation with MDM2 overexpression as five (71%) of seven DLCL with CDKN2A HD had MDM2 overexpression (P = 0.21). Four (44%) of nine p16-immunonegative tumours harboured p53 mutations, showing a trend towards a positive correlation (P = 0.14). Of seven tumours with CDKN2A deletions two had concomitant p53 mutations (P = 0.80). Interestingly, the majority, seven (78%) of nine, of p16-immunonegative tumours showed alteration of p53 and/or MDM2 (P = 0.29).
Discussion
We analysed a group of 34 primary DLCL and three recurrent DLCL for the status of several genes functioning at the nexus of the p53 and RB1 pathways. Previous studies of CDKN2A in DLCL have shown that HD are moderately common, present in 18 (11%) of 165 cases, [26] [27] [28] [29] [30] [31] similar to our 18% in primary DLCL (and 19% overall) . Point mutations of CDKN2A are rare in DLCL, seen in only one of 125 cases reported, [27] [28] [29] 32 and not detected in our material. A third major means of CDKN2A inactivation is promoter silencing by hypermethylation of the 5′ CpG island. Although some reports have shown hypermethylation in 11 (39%) of 28 cases, 29, 33, 34 we found hypermethylation in only 6% of primary DLCL (and 8% overall).
The finding of MDM2 overexpression in 43% of DLCL in this study is comparable to previous studies. 15, 16, 35 The mechanism behind this overexpression is obscure in NHL as amplification of MDM2 is rarely seen in lymphoid neoplasms overexpressing MDM2 15, 16, 35 indicating that other posttranscriptional mechanisms are responsible. [36] [37] [38] [39] [40] Splicing variation is a mechanism identified in some tumour types. Tumour-associated splice variants can retain their transforming ability even if they harbour partial deletions of the region encoding the p53 binding domain. 39 These findings suggest a tumorigenic function independent of p53. Our finding of MDM2 overexpression in 43% of p53-mutated DLCL could also indicate that there is an additive effect on lymphomagenesis of simultaneous p53 mutation and MDM2 overexpression.
MDM2 levels are also subject to regulation by proteolytic degradation mediated by p19 ARF . 6 Therefore one would expect that tumours with HD of CDKN2A (thereby inactivating p19 ARF ) would be defective in MDM2 degradation and express elevated levels of MDM2. Consistent with this, the present study shows overexpression of MDM2 in 71% (five of seven) of DLCL with CDKN2A deletions. Although the remaining two tumours have very low to undetectable levels (Ӷ1% of nuclei immunopositive) of MDM2, it cannot be excluded that these tumours harbour non-sense or frameshift mutations of MDM2 that could preclude detection of the protein. 41 The relative importance of p16 and p19 ARF in lymphoma/ leukemogenesis is at present unresolved. Deletions of all of the coding sequences of p16 and p19 ARF will of course inactivate both genes, whereas deletions or point mutations only affecting exons 2 and 3 could selectively inactivate p16. These exons are important for p16 tumour suppressive function while intact exon 1␤ has proved sufficient for p19 ARF effect in murine and human cell lines. 42, 43 Moreover, functionally analysed cancer-associated point mutations in exon 2 may inactivate p16 and not p19 ARF . 5, 42, 43 That exon 1␤ encodes p19 ARF 's MDM2 binding region 6 could explain its functional importance. The fact that mutations in lymphoid neoplasms rarely are point mutations but most often co-deletions of p15 and p16 (including exon 1␤) or deletions of p16 alone (most including exon 1␤ 44 ), combined with identification of inclusion of exon 1␤ in all of the rarer 'p15-only' deletions in acute lymphoblastic leukaemia, 45 suggests a role for p19 ARF in lymphoma/leukemogenesis. To date, no point mutations specific to exon 1␤ have been identified, 6 suggesting that coinactivation of p16, and perhaps p15 as well, confers a selective growth advantage to a tumour cell. Genetic alteration may not even be necessary for inactivation of p19 ARF . Neoplastic haematopoietic cell lines expressing abundant ␤ transcript without apparent mutations can be negative for the protein suggesting there could exist an uncoupling of transcription and translation. 46 This mechanism could be active in cases with selective p16 inactivation, eg 5′ CpG island hypermethylation. The hypothesis that p19 ARF is a tumour suppressor protein that functions in the p53 pathway predicts that tumours with inactivation of p19 ARF are less likely to harbour p53 alterations. 5 A re-examination of the literature of published mutations of CDKN2A and p53 could not definitely confirm a reciprocal relationship. 5 Reviewing the 263 cases (including the 37 reported in this study) of lymphoid neoplasia analysed for both p53 mutations and CDKN2A deletions 47-50 also did not show a sufficiently low rate of co-alterations to substan- tiate the hypothesis. On the contrary, our results imply that a second alteration of the p53 pathway components p53, p19 ARF and MDM2, results in a substantial additional growth advantage of the tumour, as compared to alteration of only one of these components.
In conclusion, p16, p19 ARF , p53 and MDM2 are frequently aberrant in DLCL and can be involved in disease progression. The results support an interaction between p19 ARF and MDM2 but alterations of the p53 pathway genes are not mutually exclusive. Future identification of new components and interactions will undoubtedly further elucidate the biology of this important aspect of lymphomagenesis. Relations to other genes involved in the RB1 pathway as well as clinical data are currently being investigated, and may be translated into new therapeutic initiatives.
